Michael Biggel - ESR5

POC Molecular IVDs generating actionable information in support of improving clinical management of UTIs

A clinically derived multiplex molecular bioassay

The clinical usefulness of any diagnostic test largely depends on the bioassay. This project aims to produce an optimal bioassay for urinary tract infections (UTI) through outreach to the end-users and assessment of the actual clinical need per setting (primary care, hospital care,…). This end-user perspective will be complemented by the actual quantification of microorganisms in urine by culture-based methods, metagenomic analysis and flow cytometry, all of which will be correlated to clinical symptoms. Important strains, such as E. coli, will be sequenced, typed and differentiated in relation to clinical outcome, infective dose and sequence specific markers of infection. Building on this information, the actual bioassay will be developed and implemented on a POC platform (link to other project).






My scientific interests include medicine, clinical and molecular biology, molecular diagnostics, Next-Generation Sequencing and bioinformatics.





RWTH Aachen University, Germany
MSc Biotechnology 2016





  • Microfluidic ChipShop GmbH
    Stockholmer Str. 20
    D – 07747 Jena
  • Kungliga Tekniska Högskolan (KTH)
    Micro and nanosystems (MST) department
    OSQULDAS VÄG 10, Stockholm


  • Kuepper J., Dickler J., Biggel M., Behnken, S., Jäger, G., Wierckx, N., Blank, L. “Metabolic engineering of Pseudomonas putida KT2440 to produce anthranilate from glucose.”, Frontiers in Microbiology (2015)
  • Pitzler C., Lülsdorf N., Biggel M., Ljubica V., Martinez R., Schwaneberg U. “A flow cytometer-based whole cell screening toolbox for directed hydrolase evolution through fluorescent hydrogels.” , Chemical Communications (2015)

Looking for interesting collaborations?